期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

贝伐单抗联合放化疗治疗晚期筛窦腺鳞癌1例及文献复习

Bevacizumab combined with chemoradiotherapy on advanced ethmoid sinus adenosquamous carcinoma: A case report
下载PDF
导出
摘要 患者，女性，41岁，因“右侧鼻塞、右眼突出伴复视2月”于2012年12月入院。体检：右侧眼球突出，活动未见异常，右侧鼻腔堵塞，右侧上颌窦区有压痛，张口齿距4cm，仲舌居中，鼻咽右顶壁黏膜增厚，双侧咽隐窝对称无变浅，双侧颈部未触及肿大淋巴结，颅神经检查：嗅觉欠敏感，右眼复视，余颅神经未见异常。头颅MR示右侧筛窦区肿块，大小约4．0cm×5．6cm×6．0cm，侵犯鼻中隔及右侧中上鼻甲、右侧鼻腔、右侧上颌窦及右侧蝶实、眼眶（图1）。胸片、B超及骨扫描末见异常。行右侧筛窦隐窝肿物活榆术，病理为右侧鼻腔筛窦腺鳞癌，因而诊断为右侧鼻腔筛窦腺鳞癌（T4bN0M0IVb期）。
作者 阳秋香 张秀萍 李果 袁太泽 梁颖 余锦秀
机构地区 广州医科大学附属肿瘤医院放疗科
出处 《现代肿瘤医学》 CAS 2015年第21期3188-3190,共3页 Journal of Modern Oncology
基金 吴阶平医学基金(编号:320.6750.12682)
关键词 贝伐单抗 放化疗 筛窦 腺鳞癌 bevacizumab, chemoradiotherpy, ethmoid sinus, adenospquamous carcinoma
分类号 R739.62 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Barham HP, Said S, Ramakrishnan VR. Colliding tumor of the para- nasal sinus[J]. Allergy & Rhinol,2013,4( 1 ) :13 - 16.
  • 2Sirsath NT, Babu KG, Das U, et al. Paranasal sinus neuroendoerine carcinoma:A case report and review of the literature[ J]. Case Rep Oncol Med,2013,2013:728479.
  • 3Suzuki S, Hanata K, Nanjo H, et al. Adenosquamous carcinoma of maxillary sinus: Case showing complete response to S - 1 [ J ]. J La- ryngol Otol,2009,123( 11 ) : 1271 - 1275.
  • 4Kajikawa H, Chatani M, Matsushiro N, et al. A case of advanced adenoearcinoma of the ethmoid sinus treated by chemoradiation with S - 1 [J]. Can To Kagaku Ryoho,2009,36(5) :871 -873.
  • 5Brahmer JR, Dahlberg SE, Gray RJ, et al. Sex differences in out- come with bevacizumab therapy [ J ]. J Thoracic Oncol, 2011,6(1) :103 -108.
  • 6赵晓辉,王季堃.贝伐单抗治疗进展期非小细胞肺癌临床疗效及安全性观察[J].中国肿瘤临床,2011,38(21):1351-1354. 被引量：4
  • 7Efstathios T Pavlidis,Theodoros E Pavlidis.Role of bevacizumab in colorectal cancer growth and its adverse effects:A review[J].World Journal of Gastroenterology,2013,19(31):5051-5060. 被引量：25
  • 8Hainsworth JD, Spigel DR, Greco FA, et al. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck:A phase II trial of the sarah cannon oncology research consortium[ J]. Cancer J,2011,17 ( 5 ) :267 - 272.
  • 9Yoo DS, Kirkpatrick JP, Craciunescu O, et al. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer [ J ]. Clin Cancer Res, 2012,18(5) :1404 - 1414.
  • 10Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyn- geal carcinoma ( RTOG 0615 ) : A phase 2 multi - institutional tri- al[ J]. Lancet Onco1,2012,13 (2) : 172 - 180.

二级参考文献39

  • 1Willerr CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer[J]. Nat Med, 2004, 10(2): 145-147.
  • 2Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase ii trial comparing bevacizumab plus carboplatin and paclitax- el with carboplatin and paclitaxel alone in previously untreated lo- cally advanced or metastatic non-small cell lung cancer[J]. J Clin Oncol, 2004, 22(11): 2184-2191.
  • 3Reck M, von PawelJ, Zatloukal P, et al. Overall survival with cispl- atin gemcitabine and bevacizumab or placebo as farst-line therapy for nonsquamous non-small-cell lung cancer: results from a ran- domised phase Ⅲ trial(AVAiL)[J]. Ann Oncol, 2010, 21(9): 1804-1809.
  • 4Reynolds C, Barrera D, Jotte R, et al. Phase II trial of nanopartide albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer[J].J Thorac Oncol, 2009, 4(12): 1537-1543.
  • 5Sandier AB, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with Bevacizumab for non-smaU-ceU lung cancer[J]. N Engl J Med, 2006, 355(24):2542-2550.
  • 6Reck M, von PawelJ, Zatloukal P, et al. Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non small-cell lung cancer: AVAIL[]]. J Clin Oncol, 2009, 27(8): 1227-1234.
  • 7Subramanian ML, Ness S, Abedi G, et al. Bevacizumab vs ranibi- zumab for age-related macular degeneration: early results of a pro- spective double-masked, randomized clinical triM[J]. AmJ Ophthal- mol, 2009, 148(6): 875-882.
  • 8Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces an- tiangiogenic effects through inhibition of epidermal groeth factor re- ceptor tyrosine kinase[J]. Cancer Res, 2002, 62(9): 2554-2560.
  • 9Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor recep- tor tyrosine kinase inhibitor, with additional activity against epider- mal growth factor receptor tyrosine kinase[J]. Clin Cancer Res, 2003, 9(4): 1546-1556.
  • 10Herbst RS,Johnson DH, Mininberg E, et al. Phase I /lI trial evalu- ating the anti-vasctflar endothelial growth factor monoclonal anti- body bevacizumab in combination with the HER-l/ epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for pa- tients with recurrent non-small-cell lung cancer[J]. Clin Oncol, 2005, 23(11) : 2544-2555.

共引文献27

现代肿瘤医学
2015年 第21期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部